XCUR
ExicureCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
A financing or strategic transaction that extends runway, plus visible follow-through on the GPCR USA program after its completed Phase 2 work, could let investors revalue XCUR above distressed levels [#10-K-2026-03-25].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Going-concern risk and very limited liquidity
Momentum
88
Value
41
Sentiment
30
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.60 · Bull $5.20 · Bear $0.90
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum88 · Δ7d -
Value41 · Δ7d +0.1
Sentiment30 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
30
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 87.9 / Value 41.1 / Sentiment 29.6
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$19.82M
Beta
4.11
Shares Out
6.37M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.05
Rev YoY
-100.0%
EPS YoY
+32.9%
Gross Margin
-
Op Margin
-2365.0%
Net Debt
-$12.51M
Current Ratio
1.96
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology